Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics
b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
- b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
- KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment.
- The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy\xe2\x80\x99s progress.
- More information on KetaDASH is available at www.ketadash.com .\nKetamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.